Amlodipine Cost in New Jersey 2026: Cash Price, Medicaid, Insurance, and Compounding

What Is Amlodipine and Why Is It Prescribed?

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA for hypertension and chronic stable or vasospastic angina. It works by relaxing peripheral and coronary arteriolar smooth muscle, lowering systemic vascular resistance and blood pressure without the reflex tachycardia seen with shorter-acting agents. The standard adult starting dose is 5 mg once daily, with titration to 10 mg; patients who are small, fragile, or elderly sometimes begin at 2.5 mg [1].

The drug's long plasma half-life of 30 to 50 hours means blood-pressure control extends evenly across 24 hours even with a single daily dose, an attribute confirmed in pharmacokinetic studies published in peer-reviewed literature [2]. Because of that consistency, the JNC 8 guideline panel listed dihydropyridine calcium channel blockers alongside thiazide diuretics and ACE inhibitors as first-line agents for most adults with hypertension [3].

Hypertension affects roughly 35% of New Jersey adults according to CDC surveillance data [4]. Given that patient burden, amlodipine dispensing volume in NJ is substantial, which is one reason generic manufacturers have driven the cash price so far below the branded list price.

Amlodipine Cash Price in New Jersey in 2026

Generic amlodipine costs approximately $8 per month at New Jersey retail pharmacies in 2026 for a 30-tablet supply at standard doses. That figure reflects GoodRx, NeedyMeds, and pharmacy-posted pricing across the state.

The brand version, Norvasc (Pfizer), carries a manufacturer list price near $80 per month. No clinical reason exists to choose the brand over a bioequivalent generic; the FDA requires AB-rated generics to meet the same bioavailability standards as the reference listed drug [5]. Pfizer lost patent exclusivity on Norvasc in 2007, and multiple generics have since been approved, producing the steep price compression visible today.

Pricing varies by pharmacy chain and by the specific strength dispensed:

• 2.5 mg tablets: often $4 to $7 per month
• 5 mg tablets: approximately $7 to $9 per month
• 10 mg tablets: approximately $8 to $12 per month

Buying a 90-day supply instead of 30 days typically shaves another 10 to 20 percent off the per-dose cost at major New Jersey chains. Several NJ retailers also list amlodipine on their $4/$10 generic programs (30-day/90-day), though individual store participation should always be confirmed directly [6].

A patient without any insurance or assistance program paying $8 per month spends $96 per year on amlodipine. That is among the lowest annual costs of any prescription antihypertensive on the US market, which reflects both patent expiry and high generic competition [7].

Does New Jersey Medicaid Cover Amlodipine?

NJ FamilyCare (New Jersey's Medicaid program) covers generic amlodipine for hypertension and angina, but a prior authorization (PA) is required for most beneficiaries before dispensing is approved [8]. The PA process typically asks the prescriber to confirm that:

1. The diagnosis meets a covered indication (hypertension, chronic stable angina, or vasospastic angina).
2. No contraindication to calcium channel blockers exists.
3. The dose prescribed falls within FDA-approved parameters [1].

Once the PA is approved, enrolled beneficiaries generally pay a nominal copay of $1 to $3 per fill, depending on their specific NJ FamilyCare eligibility category [9]. Patients receiving Medicaid through a managed care organization (MCO) contracted with the state may face slightly different PA criteria, so the prescribing clinician should check the MCO's specific formulary rather than relying solely on the fee-for-service PA criteria.

The American Heart Association estimates that inadequate blood-pressure control costs the US healthcare system more than $131 billion annually in avoidable cardiovascular events [10]. State Medicaid programs that cover low-cost antihypertensives without excessive access barriers have measurable downstream savings on hospitalizations for stroke and myocardial infarction. New Jersey's PA requirement, while a real administrative step, does not impose cost-sharing that would make adherence unaffordable for most NJ FamilyCare enrollees.

Which Commercial Insurance Plans Cover Amlodipine in New Jersey?

Generic amlodipine appears on virtually every New Jersey commercial formulary as a Tier 1 (preferred generic) drug. Tier 1 copays on ACA marketplace plans in NJ range from $0 to $10 per 30-day fill depending on plan design [11].

Patients on employer-sponsored plans should check whether their plan uses a traditional three-tier structure or a four-tier design. In a three-tier plan, preferred generics like amlodipine sit at Tier 1. In a four-tier design, amlodipine still lands at Tier 1 in most cases, because it is one of the highest-volume generics on any formulary [12].

Brand-name Norvasc is generally placed at Tier 3 or higher, meaning out-of-pocket costs for the brand range from $45 to over $100 per month even with insurance. Requesting a generic substitution at the pharmacy counter eliminates that excess cost with no clinical trade-off.

Medicare Part D enrollees in New Jersey should look for plans listing amlodipine in the formulary's preferred generic tier, where standard copays under the 2026 Part D redesign run $0 to $5 per fill for most low-income subsidy (LIS) beneficiaries and roughly $5 to $15 for standard enrollees [13]. The Inflation Reduction Act's $2,000 out-of-pocket cap, effective 2025, provides an additional backstop for patients whose total drug costs are high across multiple prescriptions [14].

Is Compounded Amlodipine Legal in New Jersey?

Yes. Licensed 503A compounding pharmacies in New Jersey may legally prepare and dispense patient-specific amlodipine formulations when a valid prescription is present and a clinical rationale exists for compounding over the commercially available product [15]. Federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies, and the New Jersey Division of Consumer Affairs licenses and inspects them [16].

Common clinical rationales for compounded amlodipine include:

• Patients who require a strength not commercially available (for example, 1 mg for pediatric dosing titration).
• Patients with documented allergies to excipients in commercially manufactured tablets.
• Oral suspension formulations for patients unable to swallow solid dosage forms.

Compounded amlodipine is NOT interchangeable with an FDA-approved product for purposes of bioequivalence labeling. The FDA does not evaluate or approve compounded preparations [17]. A 503A pharmacy may not compound amlodipine in bulk without a patient-specific prescription and may not wholesale compounded product across state lines under this designation.

The HealthRX clinical team uses a three-question framework to determine when compounding referral is appropriate for amlodipine in NJ patients:

1. Does the commercially available strength or formulation meet the patient's clinical need? If yes, prescribe the generic.
2. If no, is there an FDA-approved product in a different manufacturer's line that meets the need? If yes, prescribe that product.
3. If no to both, is there a licensed NJ 503A pharmacy with documented quality assurance practices? Only then is a compounded preparation ordered.

This sequential check keeps patients on regulated products whenever possible and reserves compounding for genuine unmet formulation needs.

Cost for compounded amlodipine at NJ 503A pharmacies varies by pharmacy and formulation. Some telehealth platforms that operate integrated dispensing workflows list patient cost as $0 per month when the compounding fee is bundled into a subscription model, though the patient should confirm whether that model is sustainable long-term and whether the pharmacy has current NJ state licensure [18].

Key Clinical Evidence Supporting Amlodipine Prescribing

Understanding why amlodipine remains a first-line agent helps patients and clinicians appreciate the value of maintaining consistent access and adherence regardless of which payment channel they use.

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) enrolled 19,257 patients with hypertension and at least three additional cardiovascular risk factors. Patients randomized to amlodipine-based therapy (with perindopril as needed) had a 23% lower risk of fatal and non-fatal stroke compared with atenolol-based therapy (P<0.0001) at a median follow-up of 5.5 years. Non-fatal myocardial infarction and fatal coronary heart disease were also lower in the amlodipine arm [19].

The ALLHAT trial (N=33,357) showed that amlodipine was non-inferior to lisinopril and chlorthalidone for the primary outcome of combined fatal coronary heart disease and non-fatal MI, and amlodipine produced a significantly lower rate of stroke vs. lisinopril (relative risk 0.77, P<0.001) [20]. ALLHAT remains the largest antihypertensive outcome trial ever conducted.

The AHA/ACC 2017 Hypertension Guideline states: "Thiazide-type diuretics, CCBs, ACEIs, and ARBs are recommended for the treatment of hypertension in the general nonblack and black patient population" [21]. Dihydropyridine CCBs like amlodipine are specifically preferred in Black patients when ACE inhibitor monotherapy response may be attenuated [22].

Short-term blood-pressure lowering with amlodipine typically becomes measurable within one to two weeks of initiation, with full effect at four to eight weeks depending on dose and baseline blood pressure [23]. Clinicians should schedule a follow-up laboratory or telehealth check-in no later than eight weeks after starting or changing dose.

Amlodipine Side Effects That May Affect New Jersey Prescribing Decisions

Peripheral edema is the most common reason patients in NJ clinical practices request a switch or dose reduction. Incidence is dose-dependent: approximately 4.5% at 5 mg and up to 11.8% at 10 mg in key trials [1]. Edema results from preferential dilation of precapillary arterioles without matched venular dilation, leading to fluid shift into interstitial space. It is not cardiac in origin and does not indicate worsening heart failure unless other clinical signs are present.

Flushing, headache, and dizziness occur in 1% to 3% of patients and are usually transient [1]. These effects are more common at initiation and tend to diminish after two to four weeks as baroreceptors adapt.

Gingival hyperplasia is a rare class effect of calcium channel blockers, reported in fewer than 1% of amlodipine-treated patients in post-marketing surveillance [24]. Patients on long-term therapy should maintain regular dental care.

Hepatic impairment slows amlodipine clearance substantially. The FDA label recommends initiating at 2.5 mg in patients with hepatic dysfunction and titrating cautiously [1]. Renal impairment does not require dose adjustment because amlodipine is predominantly hepatically metabolized.

How to Get the Cheapest Amlodipine in New Jersey

Several cost-reduction pathways are available to NJ residents in 2026.

Generic at a discount pharmacy. Walmart, Costco, and ShopRite all operate New Jersey locations with $4/month or $10/month generic programs that include amlodipine. Confirming enrollment in the specific store's program before presenting the prescription avoids confusion at the register [6].

GoodRx and NeedyMeds coupons. These free coupon platforms can bring the 30-day cash price below $8 at many NJ chain pharmacies, including CVS, Walgreens, and Rite Aid. Coupons are not insurance and cannot be combined with Medicaid or Medicare Part D at the point of sale [25].

NJ Pharmaceutical Assistance to the Aged and Disabled (PAAD). This state program helps NJ residents aged 65 and older or adults with disabilities who meet income thresholds. PAAD beneficiaries pay a flat $5 copay per prescription for covered generic drugs, including amlodipine [26].

Senior Gold. New Jersey's Senior Gold program covers prescription costs for NJ residents aged 65 and older whose income exceeds the PAAD ceiling but falls below Senior Gold's higher threshold. Copays under Senior Gold are $15 per brand prescription and $7 per generic, meaning amlodipine generic copay is $7 per fill [27].

Pfizer patient assistance. For patients who genuinely need Norvasc rather than a generic (rare but clinically possible), Pfizer's RxPathways program provides the brand free or at reduced cost to qualifying low-income patients. The program requires income documentation and a physician attestation [28].

Telehealth platforms with integrated dispensing. Several telehealth companies licensed in NJ bundle the physician visit, prescription, and 503A compounded or generic medication into a flat monthly subscription. For patients without insurance, this can reduce total cost (visit plus drug) to $20 to $50 per month. Patients should verify the platform uses a pharmacy holding a current NJ Board of Pharmacy license before submitting payment information [18].

Amlodipine via Telehealth in New Jersey

New Jersey permits telehealth prescribing of amlodipine for hypertension and angina under state law N.J.S.A. 45:1-61 et seq., which requires the prescribing clinician to establish a valid patient-provider relationship before issuing any prescription [29]. A valid relationship generally means:

• A synchronous audio-visual visit (not asynchronous questionnaire alone) for the initial prescription.
• Documentation of the patient's blood-pressure history, including home readings or prior clinic measurements.
• A plan for follow-up monitoring, including a defined blood-pressure target consistent with AHA/ACC thresholds (below 130/80 mmHg for most adults) [21].

After the initial synchronous visit, follow-up prescriptions may be issued via asynchronous messaging in most NJ telehealth platforms, provided the patient submits current blood-pressure log data and no new symptoms are reported [29].

Home blood-pressure monitoring is particularly relevant here. A meta-analysis of 52 randomized controlled trials (N=13,522) found that home blood-pressure monitoring combined with structured clinician feedback reduced systolic BP by an additional 3.2 mmHg versus usual care (P<0.001) [30]. That magnitude of reduction corresponds to a clinically meaningful decrease in stroke and MI risk over time [19].

Monitoring Parameters After Starting Amlodipine in NJ

Blood pressure should be checked at two weeks and four to eight weeks after initiating or titrating amlodipine. Target for most adults: below 130/80 mmHg per AHA/ACC 2017 guidelines [21]. For adults aged 65 and older with high comorbidity burden, SPRINT data suggest a systolic target below 120 mmHg reduced cardiovascular events by 25% (P<0.001) but increased risk of acute kidney injury [31]; the prescribing clinician must individualize based on the full clinical picture.

Laboratory monitoring: amlodipine does not require routine electrolyte or renal function monitoring the way thiazide diuretics or ACE inhibitors do. However, any patient on multiple antihypertensives should have a basic metabolic panel annually to assess baseline renal function and electrolytes [3].

Drug interactions of clinical relevance in NJ patient populations include:

• Simvastatin: Co-administration increases simvastatin exposure by up to 77%. The FDA limits simvastatin dose to 20 mg/day when combined with amlodipine [32].
• Cyclosporine: Amlodipine increases cyclosporine levels; dose adjustment and therapeutic drug monitoring are required [1].
• CYP3A4 inhibitors (clarithromycin, ketoconazole, grapefruit juice): May increase amlodipine plasma concentration, raising the risk of hypotension and edema [1].

New Jersey's large South Asian and African American populations have population-level pharmacogenomic considerations worth noting. CYP3A5 polymorphisms affect amlodipine clearance, and studies show that individuals expressing CYP3A5 metabolize amlodipine approximately 25% faster than non-expressers, which may require higher doses for equivalent blood-pressure control [33]. Pharmacogenomic testing is not yet standard practice for amlodipine prescribing but may inform dose selection in patients with unexpectedly poor response.

Comparing Amlodipine to Alternative Calcium Channel Blockers Available in New Jersey

Clinicians sometimes consider switching patients to related agents, either for cost or tolerability reasons.

Nifedipine extended-release is similarly priced at roughly $10 to $15 per month generic cash price in NJ [6]. It lacks the decades of cardiovascular outcome data that ASCOT-BPLA and ALLHAT provide for amlodipine.

Felodipine is less commonly dispensed in NJ and may cost $15 to $25 per month generic. Its primary use is hypertension; it has a more significant interaction with grapefruit juice than amlodipine does [34].

Diltiazem (non-dihydropyridine) is appropriate for patients who need rate control alongside blood-pressure lowering, for example those with atrial fibrillation. It is not interchangeable with amlodipine for most patients because its mechanism produces more chronotropic effect and less peripheral vasodilation. Generic diltiazem ER runs approximately $15 to $25 per month in NJ [6].

Given the combination of outcome trial support, once-daily dosing convenience, low cash price, and broad NJ formulary coverage, generic amlodipine remains the default first-choice CCB for most hypertensive adults in New Jersey in 2026.